Lessons learned from the discovery of sodium valproate and what has this meant to future drug discovery efforts?

References

• Burton BS. On the propyl derivates and decomposition products of ethylacetoacetate. J Am Chem Soc. 1882;3:385–395.
   Google Scholar
• Löscher W. The discovery of valproate. In: Parnham MJ, Bruinvels J, editors. Valproate (Milestones in drug therapy).  Basel: Birkhäuser; 1999.
   Google Scholar
• Meunier H, Carraz G, Meunier Y, et al. Propriétés pharmacodynamiques de l’acide n-dipropylacétique. Therapie. 1963;18:435–438.
   PubMedGoogle Scholar
• Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia. 2009;50(Suppl 3):93–130.
   PubMed Web of Science ®Google Scholar
• Carraz G, Fau R, Chateau R, et al. Communication à propos des premiere essays cliniques sur l’activité anti-épileptique de l’acide n-diporpylacétique. Ann Med-Psychol. 1964;122:577–585.
   PubMedGoogle Scholar
• Loiseau PJ. Clinical experience with new antiepileptic drugs: antiepileptic drugs in Europe. Epilepsia. 1999;40(Suppl 6):S3-8; discussion S73-74.
   Google Scholar
• Simon D, Penry JK. Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review. Epilepsia. 1975;16(4):549–573.
   PubMed Web of Science ®Google Scholar
• Terbach N, Williams RSB. Structure-function studies for the panacea, valproic acid. Biochem Soc Trans. 2009;37(Pt 5):1126–1132.
   PubMedGoogle Scholar
• Gelisse P, Genton P, Crespel A. Is there a difference between various presentations of valproate for cognitive outcome after in utero exposure? Epilepsia. 2016;57(3):523–524.
   PubMed Web of Science ®Google Scholar
• Fisher C, Broderick W. Sodium valproate or valproate semisodium: is there a difference in the treatment of bipolar disorder? Psychol Bull. [Internet]. 2003;27(12):446–448.
   Google Scholar
• Alsarra IA, Al-Omar M, Belal F. Valproic acid and sodium valproate: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2005;32:209–240.
   PubMedGoogle Scholar
• Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018;59(12):2179–2193.
   PubMed Web of Science ®Google Scholar
• Stone WE, Javid MJ. Quantitative evaluation of the actions of anticonvulsants against different chemical convulsants. Arch Int Pharmacodyn Ther. 1979;240(1):66–78.
   PubMedGoogle Scholar
• Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20(5):359–368.
   PubMed Web of Science ®Google Scholar
• Lüttjohann A, Fabene PF, van Luijtelaar G. A revised Racine’s scale for PTZ-induced seizures in rats. Physiol Behav. 2009;98(5):579–586.
   PubMed Web of Science ®Google Scholar
• Kapucu A, Üzüm G, Kaptan Z, et al. Effects of erythropoietin pretreatment on single dose pentylentetrazole-induced seizures in rats. Biotech Histochem. 2020;1–10. Online ahead of print. DOI:10.1080/10520295.2020.1713398
   PubMed Web of Science ®Google Scholar
• White HS, Smith-Yockman M, Srivastava A, et al. CHAPTER 44 - Therapeutic assays for the identification and characterization of antiepileptic and antiepileptogenic drugs. In: Pitkänen A, Schwartzkroin PA, Moshé SL, editors. Models of seizures and epilepsy [Internet]. Burlington: Academic Press; 2006. p. 539–549.
   Google Scholar
• Löscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 1994;17(2):95–134.
   PubMed Web of Science ®Google Scholar
• White BG. The antiepileptic drug development program: an example of government-industry collaboration. Prog Clin Biol Res. 1985;197:83–93.
   PubMedGoogle Scholar
• Taylor CP, Marks JL. Pharmaceutical industry screening for new antiepileptic drugs. Adv Neurol. 1998;76:41–47.
   PubMedGoogle Scholar
• Miziak B, Chrościńska-Krawczyk M, Błaszczyk B, et al. Novel approaches to anticonvulsant drug discovery. Expert Opin Drug Discov. 2013;8(11):1415–1427.
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Antiepileptic drug therapy the story so far. Seizure. 2010;19(10):650–655.
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Brivaracetam: a rational drug discovery success story. Br J Pharmacol. 2008;154(8):1555–1557.
   PubMed Web of Science ®Google Scholar
• Ngomba RT, van Luijtelaar G. Metabotropic glutamate receptors as drug targets for the treatment of absence epilepsy. Curr Opin Pharmacol. 2018;38:43–50.
   PubMed Web of Science ®Google Scholar
• van Dijkman SC, Alvarez-Jimenez R, Danhof M, et al. Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection - a long way to go. Expert Opin Drug Metab Toxicol. 2016;12(10):1143–1156.
   PubMed Web of Science ®Google Scholar
• López-Muñoz F, Shen WW, D’Ocon P, et al. A history of the pharmacological treatment of bipolar disorder. Int J Mol Sci. 2018;19(7):2143.
   PubMed Web of Science ®Google Scholar
• Harris M, Chandran S, Chakraborty N, et al. Mood-stabilizers: the archeology of the concept. Bipolar Disord. 2003;5(6):446–452.
   PubMed Web of Science ®Google Scholar
• Lempérière T. Brief history of the development of valproate in bipolar disorders. Encephale. 2001;27(4):365–372.
   PubMed Web of Science ®Google Scholar
• Lambert PA, Garraz G, Borselli S, et al. Dipropylacetamide in the treatment of manic depressive psychoses. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1978;6(1):33–36.
   PubMedGoogle Scholar
• Depakote 250mg tablets - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2020 Mar 22]. Available from: https://www.medicines.org.uk/emc/product/6102/smpc
   Google Scholar
• Sørensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand. 1988;78(4):346–348.
   PubMed Web of Science ®Google Scholar
• Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull. 2003;37(Suppl 2):5–16.
   PubMedGoogle Scholar
• Fava M. The promise and challenges of drug repurposing in psychiatry. World Psychiatry. 2018;17(1):28–29.
   PubMed Web of Science ®Google Scholar
• Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992;12(2):81–84.
   PubMed Web of Science ®Google Scholar
• Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47(2):332–372.
   PubMed Web of Science ®Google Scholar
• Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695–714.
   PubMed Web of Science ®Google Scholar
• Pinder RM, Brogden RN, Speight TM, et al. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 1977;13(2):81–123.
   PubMed Web of Science ®Google Scholar
• Turnbull DM, Howel D, Rawlins MD, et al. Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J (Clin Res Ed). 1985;290(6471):815–819.
   PubMedGoogle Scholar
• Callaghan N, Kenny RA, O’Neill B, et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry. 1985;48(7):639–644.
   PubMed Web of Science ®Google Scholar
• Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med. 1992;327(11):765–771.
   PubMed Web of Science ®Google Scholar
• Ramsay RE, Wilder BJ, Murphy JV, et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. J Epilepsy. 1992;5(1):55–60.
   Google Scholar
• Christe W, Krämer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26(3):451–460.
   PubMed Web of Science ®Google Scholar
• Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107(3):165–175.
   PubMed Web of Science ®Google Scholar
• Richens A, Davidson DL, Cartlidge NE, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG collaborative group. J Neurol Neurosurg Psychiatry. 1994;57(6):682–687.
   PubMed Web of Science ®Google Scholar
• Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The paediatric EPITEG collaborative group. Dev Med Child Neurol. 1995;37(2):97–108.
   PubMedGoogle Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–1026.
   PubMed Web of Science ®Google Scholar
• Wheless JW, Neto W, Wang S, EPMN-105 Study Group. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol. 2004;19(2):135–141.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Schmitz B, Tomson T, et al. Role of valproate across the ages. Treatment of epilepsy in adults. Acta Neurol Scand. 2006;184(Suppl.):14–27.
   Google Scholar
• Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2019;08;2:CD003032.
   PubMedGoogle Scholar
• Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019 28;381(22):2103–2113.
   PubMed Web of Science ®Google Scholar
• Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020 11;395(10231):1217–1224.
   PubMed Web of Science ®Google Scholar
• Janszky J, Tényi D, Bóné B. Valproate in the treatment of epilepsy and status epilepticus. Ideggyogy Sz. 2017;70(7–8):258–264.
   PubMedGoogle Scholar
• Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group. Epilepsy Res. 1997;26(3):423–432.
   PubMed Web of Science ®Google Scholar
• Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 1999;40(8):1141–1146.
   PubMed Web of Science ®Google Scholar
• Arzimanoglou A, Kulak I, Bidaut-Mazel C, et al. Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy. Rev Neurol (Paris). 2001;157(5):525–536.
   PubMed Web of Science ®Google Scholar
• Lovrić M, Čajić I, Petelin Gadže Ž, et al. Effect of antiepileptic drug comedication on lamotrigine concentrations. Croat Med J. 2018;59(1):13–19.
   PubMed Web of Science ®Google Scholar
• Pavuluri MN, Henry DB, Carbray JA, et al. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord. 2004;82(Suppl 1):S103–111.
   PubMedGoogle Scholar
• Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(5):409–417.
   PubMed Web of Science ®Google Scholar
• Redden L, DelBello M, Wagner KD, et al. Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol. 2009;19(1):83–89.
   PubMed Web of Science ®Google Scholar
• Salpekar JA, Joshi PT, Axelson DA, et al. Depression and suicidality outcomes in the treatment of early age mania study. J Am Acad Child Adolesc Psychiatry. 2015;54(12):999–1007.e4.
   PubMed Web of Science ®Google Scholar
• Walkup JT, Wagner KD, Miller L, et al. Treatment of early-age mania: outcomes for partial and nonresponders to initial treatment. J Am Acad Child Adolesc Psychiatry. 2015;54(12):1008–1019.
   PubMed Web of Science ®Google Scholar
• Leniger T, Pageler L, Stude P, et al. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache. 2005;45(1):42–46.
   PubMed Web of Science ®Google Scholar
• Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):281–286.
   PubMed Web of Science ®Google Scholar
• Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17(2):103–108.
   PubMed Web of Science ®Google Scholar
• Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58(11):1652–1659.
   PubMed Web of Science ®Google Scholar
• Apostol G, Pakalnis A, Laforet GA, et al. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents. Headache. 2009;49(1):36–44.
   PubMed Web of Science ®Google Scholar
• Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache. 2008;48(7):1012–1025.
   PubMed Web of Science ®Google Scholar
• Apostol G, Lewis DW, Laforet GA, et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache. 2009;49(1):45–53.
   PubMed Web of Science ®Google Scholar
• Striano P, Belcastro V. Update on pharmacotherapy of myoclonic seizures. Expert Opin Pharmacother. 2017;18(2):187–193.
   PubMed Web of Science ®Google Scholar
• Ferlazzo E, Trenite DK-N, de Haan G-J, et al. Update on pharmacological treatment of progressive myoclonus epilepsies. Curr Pharm Des. 2017;23(37):5662–5666.
   PubMed Web of Science ®Google Scholar
• Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Epilepsy Curr. 2018;18(4):260–268.
   PubMed Web of Science ®Google Scholar
• Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):74–81.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Reid K, Young AH, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2013;(10):CD003196.
   PubMed Web of Science ®Google Scholar
• Jochim J, Rifkin-Zybutz RP, Geddes J, et al. Valproate for acute mania. Cochrane Database Syst Rev. 2019;10:CD004052.
   PubMedGoogle Scholar
• Chen P, Dols A, Rej S, et al. Update on the epidemiology, diagnosis, and treatment of mania in older-age bipolar disorder. Curr Psychiatry Rep. 2017;19(8):46.
   PubMed Web of Science ®Google Scholar
• Linde M, Mulleners WM, Chronicle EP, et al. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6):CD010611.
   PubMed Web of Science ®Google Scholar
• Baillon SF, Narayana U, Luxenberg JS, et al. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2018;10(10):CD003945.
   PubMedGoogle Scholar
• Wang Y, Xia J, Helfer B, et al. Valproate for schizophrenia. Cochrane Database Syst Rev. 2016 24;11:CD004028.
   PubMedGoogle Scholar
• Guo H-L, Jing X, Sun J-Y, et al. Valproic acid and the liver injury in patients with epilepsy: an update. Curr Pharm Des. 2019;25(3):343–351.
   PubMed Web of Science ®Google Scholar
• Davoudi-Monfared E, Radmehr M, Ghaeli P, et al. A case series of severe hyperammonemia encephalopathy related to valproate: can antipsychotics increase the risk? Iran J Psychiatry. 2019;14(3):248–252.
   PubMedGoogle Scholar
• Brown LM, Cupples N, Moore TA. Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: a case series and literature review. Ment Health Clin. 2018;8(3):148–154.
   PubMedGoogle Scholar
• Rabinowich L, Shibolet O. Drug induced steatohepatitis: an uncommon culprit of a common disease. Biomed Res Int. 2015;2015:168905.
   PubMed Web of Science ®Google Scholar
• Bassett JT, Rodriguez B, Mulligan L, et al. Acute liver failure in a military recruit treated with valproic acid and harboring a previously unrecognized POLG-1 mutation. Epilepsy Behav Rep. 2019;12:100342.
   PubMedGoogle Scholar
• Hynynen J, Komulainen T, Tukiainen E, et al. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl. 2014;20(11):1402–1412.
   PubMed Web of Science ®Google Scholar
• Veroniki AA, Rios P, Cogo E, et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open. 2017;7(7):e017248.
   PubMed Web of Science ®Google Scholar
• Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016 07;11:CD010224.
   PubMedGoogle Scholar
• Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362(23):2185–2193.
   PubMed Web of Science ®Google Scholar
• Macfarlane A, Greenhalgh T. Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach? BMC Pregnancy Childbirth. 2018;18(1):200.
   PubMed Web of Science ®Google Scholar